Who owns ACADIA PHARMACEUTICALS INC (ACAD)? Elite investor 13F holders
3 tracked elite investors reported holding ACADIA PHARMACEUTICALS INC as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC, Bridgewater Associates. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | ACADIA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 42957806.00 USD | 1697937.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | ACADIA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 32449679.00 USD | 1282596.000000 | Shares | reduce | Original filing |
| Bridgewater Associates | ACADIA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1271705.00 USD | 50265.000000 | Shares | reduce | Original filing |
| Gotham Asset Management | ACADIA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.